Fed­s' case spot­lights Shkre­li’s dis­as­trous biotech short -- which forced him to launch Retrophin

A bad bet short­ing Orex­i­gen Ther­a­peu­tics’ stock back in 2011 tor­pe­doed Mar­tin Shkre­li’s hedge fund, ac­cord­ing to a for­mer staffer tes­ti­fy­ing in the Shkre­li fraud …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER